🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

About the smile: the standing ovation also meant that people saw what I knew: behind every one of these bars is a patient. I know every name and have seen almost everyone. I know their stories and their children. And I believe many are cured because of this. #ESMO22 #ChalabiPlot

Ever since #ESMO22 ESMO - Eur. Oncology I have been seeing #ChalabiPlot all over. Found this one and the likely EFS curve in the woodpile. Myriam Chalabi OncoAlert

JAGarciaMD gives a shoutout to Neeraj Agarwal, MD, FASCO Umang Swami on their work on #SPOP mutations as a predictive biomarker in mHSPC OncLive SOSS Ryon Graf, PhD Moshe Ornstein MD Christopher Wee, MD Omar Mian Emmanuel Antonarakis

Great collab evaluating hypothesis that ctDNA tumor fraction may be prognostic across cancers. Full 🧵to follow! What a team! Z Reichert Todd 〽️ Morgan, MD U-M Rogel Cancer Center, E. Castellanos et al Flatiron Health, Geoff Oxnard MD Ryon Graf, PhD Foundation Medicine The James h/t Paolo Tarantino!

Study shows that plasma cfDNA tumour fraction is a pragmatic, independent prognostic biomarker across across pts with mCRPC, mBC, advanced-stage NSCLC and mCRC, with the potential to guide clinical conversations around expected treatment outcomes: annalsofoncology.org/article/S0923-…

This article in Annals of Oncology reports on the prognostic value of ctDNA fraction across different tumor types using real-world data from a de-identified clinico-genomic database annalsofoncology.org/article/S0923-… Ryon Graf, PhD Zachery Reichert, MD, PhD Geoff Oxnard MD Todd 〽️ Morgan, MD Daniel Stover, MD, FASCO

Loving John Smoltz’s on-air hat tip to the late Tony Gwynn. I knew Gwynn did well against that Braves Hall of Fame ‘90s rotation, but I had no idea the numbers were this ridiculous. He was the best. RIP. #Padres

👀 Check out what’s popular this week in #JCOPO: Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples 👉 fal.cn/3t8RC Hatim Husain Geoff Oxnard MD #ctDNA #lcsm

Elena Castro ASCO #GU23 discussing Talapro-2 & Triton-3 abstracts. Ongoing Qs/challenges: 1. Where will PARPi best fit ? 1L mCRPC? 2L mCRPC? mHSPC? 2. Which pts? BRCA? All-comers? 3. Managing toxicities eg anemia 4. Overcoming resistance eg reversion mutations

Important take home slide from Elena Castro on PARPi role in mCRPC. BRCA>HRRm>all comers>non-HRRm #GU23

Elena Castro delivers an elegant & thoughtful discussion of TALAPRO2 Neeraj Agarwal, MD, FASCO and TRITON3 Alan H Bryce We need to understand benefit, ideally need OS benefit before using in HRR beg mCRPC pts, Toxicity can be an issue. #GU23 ASCO

Talapro-2 ⬆️ rPFS for talazoparib/enza in unselected CRPC with more benefit in HRR as with olaparib/abi. Titron-3 showed rucaparib alone ⬆️ rPFS, particularly in BRCAs. ATM fails to enrich again. OS not +ve yet in either. The biomarker is important for PARPi in CRPC IMO #ASCOGU23

Surprised to hear such emphatic support of PFS wout OS benefit for PARPi in #prostatecancer when 1 in 4 on PARPi require one or more blood transfusions. Not sure that's a fair ask of @reccross or sustainable at a public health level #GU23 Appreciate Elena Castro counterpoint

Amazing data presented from Talapro-2 by Neeraj Agarwal, MD, FASCO on the heals of Propel and Magnitude providing future support of PARPi + ARSI. Trials not powered for OS so leaves some open questions.ASCO #GU23

Beautiful summary of mCRPC treatment options with recommended algorithms by silke gillessen #GU23

OS data from PROPEL (Olaparib + Abi) in 1st line mCRPC. 7 mo median OS benefit (p=0.054). But really driven by HRRm subgroup, right? #GU23

In a letter to Cell Press' Cancer Cell, our scientists share new research demonstrating a consistent association between high tumor mutational burden (TMB-H) & outcomes on immune checkpoint inhibitors in patients of European, African & Asian ancestry: bit.ly/41sICaa

🚨Happy to share our exciting #ctDNA monitoring research in metastatic NSCLC hot off the press Clinical Cancer Research 👇aacrjournals.org/clincancerres/… Moffitt Cancer Center

🚨 New pub: real-world PARP-I response in mCRPC according to DDR alteration status. Huge credit to 💫 Michigan Urology chief resident (and future Stanford Urology YUO fellow) Daniel A. Triner MD PhD and the amazing Ryon Graf, PhD for all their work on this.

The results of SONIA are out on nature. 1L use of palbo did not improve PFS over 2L use, but led to more AEs & costs. An evolving treatment landscape challenges its interpretation— yet it shows that sequencing trials are possible. Congrats to the authors! nature.com/articles/s4158…